scholarly journals P1554A non-invasive vascular multi-marker approach for the detection of coronary artery disease and future adverse events in high cardiovascular risk patients

2018 ◽  
Vol 39 (suppl_1) ◽  
Author(s):  
G Georgiopoulos ◽  
M Lavda ◽  
T Papaioannou ◽  
A Laina ◽  
S Georgiou ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Adverse Events ◽  
High Cardiovascular Risk ◽  
Non Invasive ◽  
Risk Patients ◽  
Artery Disease

Non-invasive detection of coronary artery disease in high-risk patients based on the stenosis prediction of separate coronary arteries

2018 ◽  
Vol 162 ◽  
pp. 119-127 ◽  
Author(s):  
Roohallah Alizadehsani ◽  
Mohammad Javad Hosseini ◽  
Abbas Khosravi ◽  
Fahime Khozeimeh ◽  
Mohamad Roshanzamir ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
High Risk ◽  
Coronary Arteries ◽  
High Risk Patients ◽  
Non Invasive ◽  
Risk Patients ◽  
Artery Disease

scholarly journals The usefulness of dipyridamole stress echocardiography in high-risk patients before abdominal aneurism surgery

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
S Binno ◽  
L Moderato ◽  
P Capelli ◽  
MF Piepoli ◽  
M Scabini ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
High Risk ◽  
Stress Echocardiography ◽  
High Cardiovascular Risk ◽  
Stress Echo ◽  
Artery Disease ◽  
Dipyridamole Stress

Abstract Funding Acknowledgements Type of funding sources: None. Background  Coronary artery disease (CAD) and aortic aneurysm (AA) share commons risk factors, such as hypertension, diabetes mellitus, hypercholesterolemia, and smoking. Cardiac assessment before aortic abdominal aneurysm (AAA) surgery is indicated for patients with symptomatic coronary artery disease (CAD). The usefulness of assessment of moderate/high-risk patients is still debated.  Purpose the purpose of our study is to evaluate the safety and effectiveness of dipyridamole stress echocardiography (DSE) for the detection of CAD in patients undergoing AAA surgery with high cardiovascular risk.  Methods From 2017th to 2019th 120 patients underwent surgery for aortic aneurysm (71 endovascular technique and 49 with open laparotomy).  Of these, 74 asymptomatic patients with high cardiovascular risk underwent a pre-surgical contrast-enhanced dipyridamole stress echo (0,84 mg/kg over 6 minutes – protocol with LVO with sulfur hexafluoride), to exclude the presence of inducible myocardial ischemia, Mean follow-up was 6-24 months.  Results   Mean age was 77 years +/- 6.6, with male gender prevalent (83%).  No complication during DSE occurred; mean SCORE risk was 9.8% +/- 2.3%, with 63% patients with very high risk.  Only 1 patient showed inducible ischemia during stress echocardiography, with evidence of significant LAD stenosis; no myocardial infarction was reported at follow-up, while 1 ischemic stroke and 1 unplanned revascularization occurred.  11% of patients died, of which 50% for Sars-Cov-2 disease and 12% due to post-surgery dissection while no cardiac deaths were found. Conclusions dipyridamole stress echo is safe in patients with surgical-class abdominal aortic aneurism; in patients with high cardiovascular risk but no symptoms reversible ischemia is rare. DSE should not be routinely performed before high-risk surgery but only in patients with cardiac symptoms. Abstract Figure. Patients Diagram

Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk

2014 ◽  
Vol 30 (4) ◽  
pp. 469-476 ◽  
Author(s):  
Takayuki Fujiwara ◽  
Masashi Yoshida ◽  
Hodaka Yamada ◽  
Takunori Tsukui ◽  
Tomohiro Nakamura ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
High Cardiovascular Risk ◽  
Artery Disease

scholarly journals Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Kamel Mohammedi ◽  
Nathalie Préaubert ◽  
Tanguy Cariou ◽  
Vincent Rigalleau ◽  
Ninon Foussard ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Lower Limb ◽  
High Cardiovascular Risk ◽  
Coronary Syndrome ◽  
Artery Disease ◽  
Very High

Abstract Background Screening for coronary artery disease (CAD) remains broadly performed in patients with type 2 diabetes (T2DM), although the lack of evidence. We conduct a real-world evidence (RWE) study to assess the risk of major clinical outcomes and economic impact of routine CAD screening in T2DM individuals at a very high cardiovascular risk. Methods SCADIAB is a comparative nationwide cohort study using data from the French National Health Data System. The main inclusion criteria are: age ≥ 40 years, DT2 diagnosed for ≥ 7 years, with ≥ 2 additional cardiovascular risk factors plus a history of microvascular or macrovascular disease, except CAD. We estimated ≥ 90,000 eligible participants for our study. Data will be extracted from 01/01/2008 to 31/12/2019. Eligible participants will be identified during a first 7-year selection period (2008–2015). Each participant will be assigned either in experimental (CAD screening procedure during the selection period) or control group (no CAD screening) on 01/01/2015, and followed for 5 years. The primary endpoint is the incremental cost per life year saved over 5 years in CAD screening group versus no CAD screening. The main secondary endpoints are: total 5-year direct costs of each strategy; incidence of major cardiovascular (acute coronary syndrome, hospitalization for heart failure, coronary revascularization or all-cause death), cerebrovascular (hospitalization for transient ischemic attack, stroke, or carotid revascularization) and lower-limb events (peripheral artery disease, ischemic diabetic foot, lower-limb revascularization or amputation); and the budget impact for the French Insurance system to promote the cost-effective strategy. Analyses will be adjusted for a high-dimension propensity score taking into account known and unknown confounders. SCADIAB has been funded by the French Ministry of Health and the protocol has been approved by the French ethic authorities. Data management and analyses will start in the second half of 2021. Discussion SCADIAB is a large and contemporary RWE study that will assess the economic and clinical impacts of routine CAD screening in T2DM people at a very high cardiovascular risk. It will also evaluate the clinical practice regarding CAD screening and help to make future recommendations and optimize the use of health care resources. Trial registration ClinicalTrials.gov Identifier: NCT04534530 (https://clinicaltrials.gov/ct2/show/NCT04534530)

Sign in / Sign up

Export Citation Format

Share Document